Xilio Therapeutics, Inc. Announces Amended and Restated Director Compensation Policy Effective April 15, 2026

WALTHAM, MA, April 15, 2026 – Xilio Therapeutics, Inc. (“Xilio” or the “Company”) (Nasdaq: XLO), a biotechnology company listed on the Nasdaq Capital Market, announced via an SEC Form 8-K filing that its Board of Directors has approved and adopted an Amended and Restated Director Compensation Policy, effective April 15, 2026.

Key Points for Investors

• Adoption of Amended and Restated Director Compensation Policy: The Board of Directors formalized a new compensation structure for non-employee directors, which may have material implications on corporate governance, director recruitment, and long-term strategy alignment.
• Details of the New Compensation Policy:
  • Annual Cash Retainers:
    • Board of Directors: \$40,000 per year per non-employee director
    • Lead Independent Director: \$30,000 per year (if applicable)
  • Committee Chair and Member Fees:
    • Audit Committee: \$7,500 per year for both Chair and members
    • Compensation Committee: \$6,000 per year for both Chair and members
    • Nominating and Corporate Governance Committee: \$4,000 per year for both Chair and members
  • Equity Awards:
    • Annual equity grants and initial awards will vest over three years in equal installments, subject to continued service.
    • Full vesting will accelerate upon a director’s death, disability, or a change in control of the company.
    • Option exercise price will be set at the closing price of Xilio’s common stock on the date of grant; if the grant date is not a trading day, the exercise price will be determined under the current stock incentive plan.
  • Adjustments:
    • Share amounts for equity awards will be automatically adjusted for stock splits, reverse splits, recapitalizations, and similar changes.
  • Expense Reimbursement:
    • Non-employee directors are entitled to reimbursement for reasonable out-of-pocket business expenses for attending board/committee meetings and other board-authorized activities, in accordance with company policy.

Potential Impact on Shareholders and Share Price

• Governance and Alignment: The adoption of the revised director compensation plan is a significant governance action. Enhanced cash and equity compensation can help attract and retain qualified independent directors, which is critical as Xilio advances its strategy and pipeline.
• Change in Control Provisions: The acceleration of equity vesting upon a change in control could be seen as a “golden parachute” feature, potentially making the company more attractive to board candidates but also increasing costs in an acquisition scenario. This may be interpreted by the market as a signal that the company is preparing for potential strategic opportunities, which could be price sensitive.
• Stock-Based Compensation Expense: The new policy may increase non-cash compensation expense, which should be monitored by investors for its impact on future earnings reports.

Other Noteworthy Information

• Xilio remains an “Emerging Growth Company” as defined by the SEC, meaning it may take advantage of certain reduced reporting requirements and extended transition periods for new or revised accounting standards.
• No amendments or restatements of prior filings were indicated in this report.
• No director departures or new appointments were reported in this filing.

Conclusion

The adoption of this Amended and Restated Director Compensation Policy is a clear step by Xilio Therapeutics to position itself competitively for director talent and to align incentives as the company progresses. The inclusion of change in control acceleration and competitive cash/equity retainers are notable and may be interpreted as a preparatory move for future strategic events, potentially including partnerships, acquisitions, or other corporate actions. Investors should monitor upcoming disclosures for further developments in corporate governance and strategy.

Disclaimer: This article is based on Xilio Therapeutics, Inc.’s public SEC filings as of April 15, 2026. It is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. The author and publisher take no responsibility for actions taken based on this information.

View Xilio Therapeutics, Inc. Historical chart here